Mylan Specialty LP
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1978-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
4
CANADA:2
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Phase 2
Completed
- Conditions
- Post Operative PainAcute PainPain
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Mylan Specialty, LP
- Target Recruit Count
- 111
- Registration Number
- NCT05317312
- Locations
- 🇺🇸
Research Facility 201, Salt Lake City, Utah, United States
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Phase 2
Terminated
- Conditions
- Amanita PoisoningMushroom PoisoningAmatoxin PoisoningLiver Failure
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Mylan Specialty, LP
- Target Recruit Count
- 148
- Registration Number
- NCT00915681
- Locations
- 🇺🇸
Recruitment Hot Line for the United States, Somerset, New Jersey, United States
🇺🇸Mylan Specialty LLP, Morgantown, West Virginia, United States
News
No news found